A class at Washington University taps directly into the astonishing motivational power of the mashup of computers, gaming and popular culture. In the class, the students develop applications, popularly known as “apps,” for the iPhone and iPad, the digital tablet that was released to consumers April 3.
Writer Tatyana Tolstaya, one of the foremost chroniclers of post-Gorbachev Russia, will present a pair of events at Washington University April 5 and 6. Tolstaya is the Visiting Fannie Hurst Professor of Creative Literature in The Writing Program in the Department of English in Arts & Sciences.
Regarded as one of the nation’s leading African historians, Jean Allman, PhD, shares her passion for the continent through her teaching, mentoring of undergraduate and graduate students, prolific writing and worldwide scholarly presentations, and editorship of a book series that ensures other scholars’ writings about African history are published.
For many WUSTL students, faculty and staff, Metro provides an environmentally friendly and economical commute to campus, work and social events. St. Louis County voters will decide April 6 whether to pass Proposition A, which calls for a half-cent sales tax increase to support public transportation in the St. Louis area.
Evan D. Kharasch, MD, PhD, the Russell D. and Mary B. Shelden Professor of Anesthesiology and professor of biochemistry and molecular biophysics, has been appointed vice chancellor for research at Washington University in St. Louis, effective April 5. He had served as interim vice chancellor since July 2009. As the chief officer responsible for the university’s research mission, he will oversee an enterprise that generates more than $500 million annually for sponsored research from a wide array of funding sources.
Of note Jeffrey Bradley, MD, the S. Lee Kling Associate Professor of Radiation Oncology, was named the lung cancer committee chair for the Radiation Therapy Oncology Group. As chair, Bradley will serve on the RTOG Research Strategy Committee and work closely with investigators from the group’s scientific core committees to develop and report on protocols […]
A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.